Treatment of schizophrenia. Maintaining the achieved clinical effect with long-term therapy in patients who had a response to initial therapy. Treatment of moderate to severe manic episodes. Prevention of repeated attacks in patients with bipolar disorders who received a positive response in the treatment of olanzapine mania.
active substance: 1 film-coated tablet contains 5 mg or 7.5 mg or 10 mg or 15 mg or 20 mg of olanzapine (equivalent to 7.03 mg or 10.55 mg or 14.06 mg, or 21.09 mg, or 28.12 mg of olanzapine dihydrochloride trihydrate, respectively);
Egolanza excipients: microcrystalline cellulose, lactose monohydrate, hyprolose (hydroxypropylcellulose), crospovidone, magnesium stearate;
shell composition: oradry Y-1-7000 white (hypromellose, titanium dioxide (E 171), macrogol 400), hypromellose, quinoline yellow (E 104).
Egolanza Dosage form
Basic physical and chemical properties:
5 mg: yellow, oblong, biconvex film-coated tablets, odorless or almost odorless, scored on one side, engraved with the stylized letter “E” and the number “402” on the other side;
7.5 mg: yellow, round, biconvex film-coated tablets, odorless or almost odorless, engraved with the stylized letter “E” and the number “403” on one side;
10 mg: yellow, round, biconvex film-coated tablets, odorless or almost odorless, engraved with the stylized letter “E” and the number “404” on one side;
15 mg: yellow, round, biconvex film-coated tablets, odorless or almost odorless, engraved with the stylized letter “E” and the number “405” on one side;
20 mg: yellow, round, biconvex, film-coated tablets, engraved with the stylized letter “E” and the number “406” on one side.
Antipsychotics. ATX code N05A H03.
Olanzapine is an antipsychotic, antimanic, mood-stabilizing drug with a broad spectrum of pharmacological action due to exposure to various receptors.
The affinity of olanazpine with some receptors (Ki; <100 nM) – serotonin 5HT2A / 2C, 5-HT3, 5-HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors m1-m5; adrenergic α1 receptor and histamine H1 receptor. Electrophysiological studies have shown that olanzapine selectively reduces the excitability of mesolimbic (A10) dopaminergic neurons, with little effect on the striatal (A9) pathways associated with motor function. Olanzapine inhibits the conditioned avoidance reflex, indicating its antipsychotic activity at doses lower than those causing catalepsy, which is a sign of motor side effects. Unlike some other antipsychotic drugs, olanzapine enhances responses to stimuli during an anxiolytic test.
Olanzapine is indicated for the treatment of schizophrenia.
Olanzapine is effective in maintaining the clinical effect achieved during long-term therapy in patients who have responded to initial therapy.
Olanzapine is indicated for the treatment of moderate to severe manic episodes.
Olanzapine is indicated for the prevention of relapses in patients with bipolar disorder who have received a positive response to olanzapine mania.
Hypersensitivity to the active substance or to any of the excipients of the drug; known risk of angle-closure glaucoma.